{"id":"insulin-glargine-100-u-ml","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201497","moleculeType":"Protein"},"_fixedAt":"2026-03-30T14:00:06.088504","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glargine is a recombinant human insulin analog modified to have an extended duration of action (up to 24 hours), providing steady basal insulin coverage. It binds to the insulin receptor on target tissues (muscle, adipose, liver) to facilitate glucose transport into cells and inhibit gluconeogenesis. This mimics the physiological basal insulin secretion pattern in non-diabetic individuals.","oneSentence":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization while suppressing hepatic glucose production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:10.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"_fixedFields":["pubmed(159)"],"trialDetails":[{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT05552859","phase":"PHASE4","title":"Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-12-05","conditions":"Type 2 Diabetes Mellitus, Renal Impairment","enrollment":62},{"nctId":"NCT05662332","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-01-14","conditions":"Type 2 Diabetes, T2D","enrollment":795},{"nctId":"NCT07070752","phase":"PHASE3","title":"Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2023-04-14","conditions":"Type 1 Diabetes Mellitis","enrollment":224},{"nctId":"NCT05462756","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-11","conditions":"Type 2 Diabetes, Type 2 Diabetes Treated With Insulin","enrollment":730},{"nctId":"NCT05036876","phase":"NA","title":"Degludec Glargine U300 Hospital Study","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2021-10-10","conditions":"Type 2 Diabetes","enrollment":220},{"nctId":"NCT03371082","phase":"PHASE3","title":"Gan & Lee Insulin Glargine Target Type (1) Evaluating Research","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2017-10-31","conditions":"Diabetes Mellitus, Type 1","enrollment":576},{"nctId":"NCT03874715","phase":"PHASE3","title":"Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 1 Diabetes Mellitus","enrollment":210},{"nctId":"NCT05457933","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-07-29","conditions":"Type2diabetes, Coronary Artery Disease","enrollment":250},{"nctId":"NCT04605991","phase":"PHASE3","title":"A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-04","conditions":"Type 2 Diabetes","enrollment":187},{"nctId":"NCT03952130","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-29","conditions":"Type 1 Diabetes Mellitus","enrollment":354},{"nctId":"NCT03371108","phase":"PHASE3","title":"Gan & Lee Insulin Glargine Target Type (2) Evaluating Research","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2017-10-31","conditions":"Diabetes Mellitus, Type 2","enrollment":567},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT03211858","phase":"PHASE3","title":"Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-08-02","conditions":"Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus","enrollment":597},{"nctId":"NCT03434119","phase":"PHASE3","title":"Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-02-20","conditions":"Type 2 Diabetes Mellitus","enrollment":241},{"nctId":"NCT02735044","phase":"PHASE3","title":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-04-14","conditions":"Type 1 Diabetes Mellitus","enrollment":463},{"nctId":"NCT01499082","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":807},{"nctId":"NCT01499095","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":811},{"nctId":"NCT03952143","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-27","conditions":"Type 2 Diabetes Mellitus","enrollment":628},{"nctId":"NCT03740919","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-07","conditions":"Type 1 Diabetes Mellitus","enrollment":751},{"nctId":"NCT03751657","phase":"PHASE2","title":"A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-11-29","conditions":"Diabetes Mellitus, Type 2","enrollment":247},{"nctId":"NCT03338023","phase":"PHASE3","title":"A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-23","conditions":"Type 1 Diabetes","enrollment":272},{"nctId":"NCT02320721","phase":"PHASE3","title":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1014},{"nctId":"NCT03352674","phase":"PHASE2","title":"Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2016-09","conditions":"Diabetes Mellitus","enrollment":133},{"nctId":"NCT03214380","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-14","conditions":"Type 2 Diabetes Mellitus","enrollment":933},{"nctId":"NCT04236895","phase":"PHASE1","title":"PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2018-07-10","conditions":"Diabetes Mellitus, Type 1","enrollment":114},{"nctId":"NCT02451137","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-16","conditions":"Diabetes Mellitus, Type 2","enrollment":3304},{"nctId":"NCT01654380","phase":"PHASE1","title":"A Study of LY2605541 Versus Insulin Glargine on Blood Sugar","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Healthy Volunteers, Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT01194245","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 1","enrollment":135},{"nctId":"NCT02738151","phase":"PHASE4","title":"Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-19","conditions":"Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT02443402","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Coronary Artery Disease","enrollment":68},{"nctId":"NCT02294474","phase":"PHASE3","title":"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":505},{"nctId":"NCT02273180","phase":"PHASE3","title":"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-10","conditions":"Type 1 Diabetes Mellitus","enrollment":507},{"nctId":"NCT02058147","phase":"PHASE3","title":"Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-02","conditions":"Type 2 Diabetes","enrollment":1170},{"nctId":"NCT02058160","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":736},{"nctId":"NCT01476475","phase":"PHASE2","title":"Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-11","conditions":"Type 2 Diabetes Mellitus","enrollment":323},{"nctId":"NCT01683266","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-09","conditions":"Type 1 Diabetes Mellitus","enrollment":549},{"nctId":"NCT01676220","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT01658579","phase":"PHASE2","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Type 1 Diabetes Mellitus","enrollment":59},{"nctId":"NCT00883558","phase":"PHASE2","title":"Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT01194258","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type II","enrollment":132},{"nctId":"NCT01121835","phase":"PHASE4","title":"Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":934},{"nctId":"NCT00069784","phase":"PHASE3","title":"The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-08","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":12537},{"nctId":"NCT01357603","phase":"PHASE1","title":"Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2011-06","conditions":"Type1 Diabetes","enrollment":111},{"nctId":"NCT00941369","phase":"PHASE4","title":"Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Diabetes Mellitus, Type 2","enrollment":345},{"nctId":"NCT00851903","phase":"PHASE3","title":"Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Diabetes Mellitus, Type 2","enrollment":112},{"nctId":"NCT00751114","phase":"PHASE4","title":"Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-11","conditions":"Diabetes Mellitus, Type 2","enrollment":515},{"nctId":"NCT00993473","phase":"PHASE3","title":"6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 1 Diabetes Mellitus","enrollment":125},{"nctId":"NCT01081938","phase":"PHASE4","title":"Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT00174642","phase":"PHASE3","title":"Opposing Step-by-step Insulin Reinforcement to Intensified Strategy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-12","conditions":"Diabetes Mellitus, Type 2","enrollment":811}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"RENAL FAILURE"},{"count":2,"reaction":"RHABDOMYOLYSIS"},{"count":1,"reaction":"ACUTE RESPIRATORY DISTRESS SYNDROME"},{"count":1,"reaction":"COMPARTMENT SYNDROME"},{"count":1,"reaction":"EMBOLISM"},{"count":1,"reaction":"ENCEPHALOPATHY"},{"count":1,"reaction":"MALAISE"},{"count":1,"reaction":"OSTEONECROSIS"},{"count":1,"reaction":"PANCREATITIS NECROTISING"},{"count":1,"reaction":"PERIPHERAL ARTERY OCCLUSION"}],"_approvalHistory":[],"publicationCount":159,"recentPublications":[{"date":"2026 Mar","pmid":"41697523","title":"Summary of Research: Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis.","journal":"Diabetes therapy : research, treatment and education of diabetes and related disorders"},{"date":"2026 Jan","pmid":"41084959","title":"Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.","journal":"Diabetes, obesity & metabolism"},{"date":"2025 Dec","pmid":"41065904","title":"Efficiency of Gla-300 versus Gla-100 Across Age Groups in People Living with Type 2 Diabetes in France: A Post Hoc Analysis of an Observational Longitudinal Study.","journal":"Advances in therapy"},{"date":"2025 Oct","pmid":"40785322","title":"Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.","journal":"Diabetes, obesity & metabolism"},{"date":"2025 Aug","pmid":"40719033","title":"Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.","journal":"Diabetes, obesity & metabolism"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lantus"],"phase":"marketed","status":"active","brandName":"Insulin glargine, 100 U/ml","genericName":"Insulin glargine, 100 U/ml","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}